Study Details
Design, interventions, and primary outcomes
About This Study
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Design
Interventions / Regimen
- Drug: Neratinib Oral Tablet — 240mg oral daily. Dosing will follow standard dose escalation procedures
- Drug: Ruxolitinib Oral Tablet — 20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
Primary Outcomes
- Objective Response Rate (18 months)
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-09-16
Completion: 2027-12
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
- Joyce A O'Shaughnessy, MD (PRINCIPAL_INVESTIGATOR) - Baylor Scott & White The Heart Hospital
- Drug: Neratinib Oral Tablet — 240mg oral daily. Dosing will follow standard dose escalation procedures
- Drug: Ruxolitinib Oral Tablet — 20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure